News

TrumpRx launched as a government-branded, direct-to-consumer discount platform for select brand-name drugs, but critics argue its cash-only savings may be limited, potentially misleading, and less cost-effective over time than traditional insurance or other programs.

JHVEPhoto-stock@adobe.com

Cigna reported 11% revenue growth for 2025. Company executives focused on several key issues in its call with investors: its settlement with the Federal Trade Commission, a transformation announced last year to move to a rebate-free model in pharmacy benefits, and a focus on patient affordability.